Saturday 17 October 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
128.75
7.80
−5.71%
Follow PTGX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 1 | 4 | 2 | 4 | 5 | 5 | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.62 | 0.00 |
P/S ratio |
— | 0.00 | 4.87 | 790.27 | 24.22 | 57.91 | 11.62 | 29.23 | 5.47 | 120.66 |
Altman Z-Score |
— | 4.41 | 2.12 | (1.37) | 8.50 | 18.20 | 6.29 | 34.73 | 22.48 | 61.55 |
Altman Z″-Score (non-manufacturers) |
— | 3.70 | 4.30 | (2.30) | 7.92 | 5.94 | 1.99 | 15.38 | 15.80 | 13.41 |
P/FCF ratio |
— | 116.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.00 | 99.01 |
P/Operating CF |
— | (26.45) | (14.85) | (12.78) | (36.75) | (58.81) | (16.71) | 78.38 | (81.45) | (150.17) |
Beneish M-Score |
— | — | (1.24) | 151.71 | 106.46 | (3.31) | (3.84) | 405.14 | 29.24 | (7.18) |
P/B ratio |
— | 3.10 | 1.34 | 2.28 | 2.48 | 5.28 | 2.45 | 3.95 | 3.52 | 9.03 |
Price to Tangible BV |
— | 3.10 | 1.34 | 2.28 | 2.48 | 5.28 | 2.45 | 3.95 | 3.52 | 9.03 |
EV/Sales |
— | 0.00 | 0.70 | 256.80 | 13.88 | 46.32 | 6.62 | 21.93 | 4.53 | 108.55 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.97 | 0.00 |
EV/Operating CF |
— | 59.46 | (0.43) | (1.43) | (5.48) | (11.75) | (2.78) | (14.20) | 10.68 | 86.61 |
EV/FCF |
— | 71.81 | (0.43) | (1.40) | (5.45) | (11.63) | (2.76) | (14.08) | 10.76 | 89.07 |
Quick Ratio |
12.41 | 3.43 | 5.10 | 3.95 | 7.66 | 7.46 | 7.61 | 16.53 | 12.32 | 12.49 |
Current Ratio |
12.94 | 3.55 | 5.26 | 4.10 | 7.84 | 7.74 | 7.80 | 16.71 | 12.48 | 12.71 |
Net Debt/EBITDA |
2.41 | 3.91 | 3.10 | 1.57 | 4.95 | 2.70 | 1.85 | 3.60 | (1.70) | 3.49 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 6.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.16 | 0.20 | 0.00 | 0.12 | 0.08 | 0.09 | 0.20 | 0.79 | 0.07 |
Operating CF/Net income |
0.79 | (0.10) | 1.28 | 0.54 | 1.10 | 0.86 | 0.85 | 0.89 | 0.67 | (0.44) |
Capex/Depreciation |
(0.80) | (0.61) | (0.66) | (0.50) | (0.17) | (0.24) | (0.28) | 0.48 | 0.23 | 0.37 |
Interest Coverage |
(134.98) | (40.32) | (16.60) | (476.46) | (107.89) | (284.07) | (32.36) | — | — | — |
| (125.46%) | (35.50%) | (33.39%) | (80.20%) | (36.79%) | (43.32%) | (49.41%) | (28.59%) | 54.39% | (20.18%) | |
| (69.34%) | (28.68%) | (25.67%) | (52.44%) | (27.60%) | (37.36%) | (42.78%) | (26.06%) | 49.91% | (18.42%) | |
ROIC |
(205.27%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 61.64% | (208.75%) |
Return on Tangible Assets |
(48.77%) | (33.82%) | (34.69%) | (69.17%) | (23.90%) | (42.06%) | (59.68%) | (23.53%) | 50.27% | (24.28%) |
Average Days of Receivables |
0.00 | 33.04 | 54.14 | 10,673.48 | 30.93 | 20.89 | 0.14 | 60.83 | 138.63 | 0.96 |
Research and Development Expense of Revenue |
0.00% | 230.18% | 192.39% | 28,139.83% | 260.26% | 460.60% | 474.83% | 200.27% | 31.80% | 346.16% |
Selling, General and Administrative Expense of Revenue |
0.00% | 58.71% | 44.29% | 6,817.75% | 65.10% | 99.41% | 119.40% | 55.82% | 10.00% | 97.47% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 21.14% | 22.37% | 3,616.02% | 27.59% | 59.93% | 91.05% | 48.82% | 8.64% | 99.91% |
Graham Net Nets |
— | 0.29 | 0.73 | 0.39 | 0.39 | 0.19 | 0.40 | 0.25 | 0.22 | 0.09 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.25 | 0.00 |
Earnings Yield |
— | (10.26%) | (25.56%) | (42.55%) | (9.92%) | (7.89%) | (24.12%) | (6.32%) | 11.61% | (2.35%) |
Free Cash Flow Yield |
— | 0.86% | (33.51%) | (23.28%) | (10.52%) | (6.88%) | (20.60%) | (5.33%) | 7.69% | 1.01% |
Revenue per Share |
0.00 | 1.13 | 1.38 | 0.01 | 0.83 | 0.59 | 0.54 | 1.06 | 7.06 | 0.72 |
Operating CF per Share |
(4.61) | 0.22 | (2.23) | (1.60) | (2.11) | (2.33) | (2.20) | (1.24) | 2.99 | 0.91 |
Capex per Share |
(0.05) | (0.04) | (0.02) | (0.04) | (0.01) | (0.02) | (0.02) | (0.01) | (0.02) | (0.02) |
Free Cash Flow per Share |
(4.66) | 0.18 | (2.25) | (1.64) | (2.12) | (2.35) | (2.22) | (1.25) | 2.97 | 0.88 |
Cash per Share |
11.94 | 8.14 | 5.76 | 5.14 | 8.89 | 7.06 | 4.84 | 6.02 | 6.80 | 8.92 |
Shareholders Equity per Share |
13.47 | 6.82 | 5.03 | 3.09 | 8.13 | 6.48 | 4.40 | 5.93 | 10.97 | 9.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
13.47 | 6.82 | 5.03 | 3.09 | 8.13 | 6.48 | 4.40 | 5.93 | 10.97 | 9.67 |
Free Cash Flow |
(30.32) | 3.21 | (50.43) | (42.49) | (72.95) | (108.97) | (108.93) | (70.84) | 182.80 | 56.08 |
Working Capital |
76.81 | 108.39 | 111.35 | 109.91 | 275.37 | 296.72 | 211.90 | 334.30 | 544.24 | 532.13 |
Capital Expenditures |
(0.35) | (0.67) | (0.49) | (0.97) | (0.47) | (1.10) | (0.79) | (0.61) | (1.35) | (1.59) |
Net Current Asset Value |
76.81 | 107.85 | 110.55 | 70.36 | 270.74 | 293.06 | 210.76 | 334.30 | 522.21 | 524.09 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.78 | 0.00 |
Capex to Sales |
0.00 | 0.03 | 0.02 | 4.19 | 0.02 | 0.04 | 0.03 | 0.01 | 0.00 | 0.03 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.40 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.77 | 1.24 | 0.85 | 1.15 | 1.89 | 2.56 | 1.80 | (1.05) | (1.87) | (1.13) |
Cash ROIC |
(18.36%) | 1.21% | (20.89%) | (19.07%) | (12.46%) | (17.38%) | (24.05%) | (10.44%) | 16.71% | 4.74% |
Accounts Receivable Turnover |
0.00 | 9.89 | 9.66 | 0.04 | 6.24 | 13.71 | 33.73 | 11.99 | 4.96 | 0.56 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
2.73 | 2.03 | 3.20 | 5.67 | 4.59 | 2.00 | 0.79 | 5.01 | 87.50 | 82.56 |
Average Payables |
1.21 | 1.21 | 4.01 | 5.41 | 4.93 | 4.15 | 3.10 | 2.24 | 1.20 | 3.48 |
Average Assets |
54.42 | 128.86 | 151.60 | 147.19 | 239.69 | 336.08 | 297.81 | 302.94 | 551.34 | 706.46 |
Average Common Equity |
30.08 | 104.09 | 116.57 | 96.24 | 179.79 | 289.81 | 257.81 | 276.14 | 505.99 | 645.00 |
Columns are period end dates